National Health Investors Receives Buy Rating and $81 Price Target from Bank of America Securities

Bank of America Securities reiterated a Buy rating on National Health Investors (NHI) with a price target of $81.00. Analyst Jeffrey Spector has a 46.63% success rate and a 3.2% average return. The consensus rating on NHI is a Strong Buy with an average price target of $80.33, representing a 12.82% upside.

National Health Investors, Inc. (NYSE: NHI) has received a strong show of support from analysts and institutional investors, with a majority rating the stock as a "Buy" or "Strong Buy." This positive sentiment is reflected in the company's recent price performance and earnings reports.

Analyst Ratings and Price Targets

Several major brokerages have initiated coverage on NHI, with most analysts assigning a "Buy" or "Strong Buy" rating. According to MarketBeat Ratings, NHI has an average recommendation of "Buy" from five research firms, with one analyst rating the stock with a "Hold" recommendation, three with a "Buy" recommendation, and one with a "Strong Buy" recommendation. The average 1-year price target among these firms is $84.60 [1].

Bank of America Securities has reiterated a "Buy" rating on NHI, setting a price target of $81.00. Analyst Jeffrey Spector, who has a 46.63% success rate and a 3.2% average return, supports this rating [3]. The consensus rating on NHI is a "Strong Buy" with an average price target of $80.33, representing a 12.82% upside [3].

Institutional Investor Activity

Institutional investors have also shown increased interest in NHI. Wealth Enhancement Advisory Services LLC, SG Americas Securities LLC, Sumitomo Mitsui Trust Group Inc., Farther Finance Advisors LLC, and Victory Capital Management Inc. have all increased their holdings in NHI during the first quarter. Institutional investors now own 62.51% of the company's stock [1].

Earnings and Dividend

NHI reported earnings of $1.15 per share for the quarter, beating the consensus estimate by $0.02. The company's net margin was 41.15%, and its return on equity was 10.64%. Revenue for the quarter was $68.87 million, up 9.6% on a year-over-year basis [1]. NHI also recently declared a quarterly dividend of $0.90 per share, with an annualized yield of 5.07% [1].

Conclusion

The combination of positive analyst ratings, increased institutional investment, and strong earnings reports suggests that NHI is well-positioned for continued growth. The company's strong financial performance and favorable analyst consensus make it an attractive investment opportunity for investors seeking exposure to the real estate investment trust sector.

References

[1] https://www.marketbeat.com/instant-alerts/national-health-investors-inc-nysenhi-given-average-rating-of-buy-by-brokerages-2025-07-10/
[2] https://www.ainvest.com/news/blue-owl-truist-securities-initiates-coverage-buy-rating-pt-17-2507/
[3] https://www.tipranks.com/stocks/nhi/forecast